Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 5Phase 3 4Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Not yet recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2

Conditions

Colorectal Neoplasms 86Ovarian Neoplasms 33Breast Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Colonic Neoplasms 23Rectal Neoplasms 21Fallopian Tube Neoplasms 17Neoplasms 16Neoplasm Metastasis 13Carcinoma, Hepatocellular 13Glioblastoma 11Lung Neoplasms 10Brain Neoplasms 8Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Intestinal Neoplasms 5Gastrointestinal Neoplasms 5Digestive System Neoplasms 5Brenner Tumor 5Recurrence 4Peritoneal Neoplasms 4Glioma 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma of Lung 4Rectal Diseases 3Non-Squamous Non-Small Cell Lung Cancer 3Liver Neoplasms 3Intestinal Diseases 3Gastrointestinal Diseases 3

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × Bevacizumab × Clear all
NCT05718466 2023-07-17

Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy

Henry Ford Health System

Phase 3 Completed
35 enrolled 13 charts
CNS

Glioblastoma, Recurrence

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Guangzhou Gloria Biosciences Co., Ltd.

Phase 3 Not yet recruiting
424 enrolled

Recurrence

NCT02761070 2023-03-08

RE-GEND

Kyorin University

Phase 3 Unknown
146 enrolled
CNS

Glioblastoma, Recurrence, Disease Progression

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
368 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡